|
||||||||
Company Profile | ||||||||
Chairman | CEO | Spokesperson | Tel | Address | Date of Listing (Regular) | |||
---|---|---|---|---|---|---|---|---|
Chuan Lin | Sze Yuan Yang | Sze Yuan Yang | 02-2655-8525 | 3F-1,No.3-1, Park St., Nangang Dist.,Taipei,Taiwan, R.O.C. | 2012/04/30 | |||
Industry | Main Business | |||||||
Biotechnology and Medical Care | TSH Biopharm Co., Ltd. was one of the business units of TTY Biopharm and formed in 2003, later spin-off from parent company in late 2010. Since its spin-off, TSH Biopharm has been dedicated to the drug development of cardiovascular, gastrointestinal and autoimmune disease as well as the marketing of new drugs in Asia. TSH Biopharm is developing Taiwan and ASEAN New Chemical Entity and Global 505(b)2 products in chronic diseases, especially in CV, GI and autoimmune fields. At the same time, TSH is also establishing sales force in Asian countries, especially in SEA. In order to achieve our goal in a short time. TSH recently expands our collaboration model which does not only reply on CDMO but also in-licensing and co-development. TSH keeps finding out suitable products to enhance our portfolio in target markets and look forward to any kind of collaboration in our interested fields since TSH believes through collaboration can help itself go faster and better. |
Market Information ( 2024/03/28 ) | |||||||||||
Shr. Vol. | Highest | Lowest | Closed | Change | Transaction | TurnOver(%) | long margin balance (1,000shr.) |
Short margin balance (1,000shr.) |
|||
---|---|---|---|---|---|---|---|---|---|---|---|
99.745 | 59.20 | 57.90 | 58.50 | 0.20 | 171 | .00 | 620 | 0 | |||
Trading method | Fun purchase price or securities pneeded on T day |
Announcement of Irregularity (2024/03/28) |
TPEx measures adopted (2024/03/28) |
With warrants | Can be shorted or margined? | Detail | |||||
Normal | N | N | N | N | Y | Today | History |
Financial Reports | |||||
---|---|---|---|---|---|
Cash Flows | Items | ||||
Amount (NT$ thousand) |
|||||
Cash flows from operating activities | |||||
Cash flows from investing activities | |||||
Cash flows from financing activities | |||||
Balance Sheets |
Current assets | ||||
Non-current assets | |||||
Total assets | |||||
Current liabilities | |||||
Non-current liabilities | |||||
Total liabilities | |||||
Share capital | |||||
Capital surplus | |||||
Retained earnings | |||||
Other equity interest | |||||
Treasury shares | |||||
Total equity attributable to owners of parent | |||||
Non-controlling interests | |||||
Total equity | |||||
Book Value per share(NT$) | |||||
Comprehensive Income | Operating revenue | ||||
Operating costs | |||||
Gross profit from operations | |||||
Operating expenses | |||||
Net other income (expenses) | |||||
Net operating income | |||||
Non-operating income and expenses | |||||
Profit before tax | |||||
Tax expense | |||||
Profit from continuing operations | |||||
Profit from discontinued operations | |||||
Profit | |||||
Other comprehensive income | |||||
Comprehensive income | |||||
Basic earnings per share |
Auditor's report on latest financial statements: auditor's report: |
More detail:MOPS。 |
Foreign issuers’ information is disclosed in consolidated statements. |